The London Stock Exchange saw its largest delisting wave since 2009 in 2024, with 88 companies exiting amid liquidity ...

US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...

Businessman Cathal Friel’s Poolbeg Pharma is exploring a possible merger that would see the business shift its listing to the ...

The London Stock Exchange (LSE) saw the largest outflow of companies since the global financial crisis during last year, ...

The all-share merger – which, if completed, would see Poolbeg de-list from the London Stock Exchange's AIM – would create a "strong clinical-stage biopharmaceutical company focused on ...

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.

A ‘lack of enthusiasm’ for London’s top stock market index nevertheless meant it lagged behind its US rival for another year, ...

As the week progresses, eyes turn to US jobs data, with a host of readings culminating with Friday's nonfarm payrolls. "We get our first major market event of the calendar year on Friday, when nonfarm ...

The latter flags that “the more affordable markets in the north” will experience the strongest house price growth in the ...

The London Stock Exchange disputes that it is falling behind ... was shrinking at its fastest pace in history because of the mergers and acquisitions (M&A) boom. As the market shrinks, it becomes ...

in early morning trading on Friday on the London Stock Exchange — a three-year low — having dropped 13.7% to $3.15 on the New York Stock Exchange at the close of play on Thursday. Holders of ...